Shares of Sanofi SA (EPA:SAN) have received an average recommendation of “Hold” from the seventeen brokerages that are currently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, eleven have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is €77.65 ($90.29).
Several equities analysts recently commented on the stock. Cfra set a €68.00 ($79.07) target price on shares of Sanofi and gave the company a “neutral” rating in a report on Monday, April 30th. Goldman Sachs Group set a €74.00 ($86.05) target price on shares of Sanofi and gave the company a “neutral” rating in a report on Monday, April 30th. Credit Suisse Group set a €80.00 ($93.02) price target on shares of Sanofi and gave the stock a “buy” rating in a report on Monday, April 30th. Deutsche Bank set a €88.00 ($102.33) price target on shares of Sanofi and gave the stock a “buy” rating in a report on Monday, April 30th. Finally, Jefferies Financial Group set a €72.00 ($83.72) price target on shares of Sanofi and gave the stock a “neutral” rating in a report on Friday, April 13th.
Sanofi opened at €66.17 ($76.94) on Monday, MarketBeat reports. Sanofi has a 52 week low of €63.09 ($73.36) and a 52 week high of €92.97 ($108.10).
About Sanofi
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio, an oral immunomodulator and Lemtrada, a monoclonal antibody to treat multiple sclerosis.